Abstract: SA-PO0671
Adverse Clinical Outcomes and Economic Burden of Corticosteroid Use in IgAN: A US Real-World Study
Session Information
- Glomerular Diseases: Clinical, Outcomes, and Therapeutics Research - Other
October 24, 2026 | Location: Exhibit Hall A, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics
Authors
- Du, Ella Xiaoyan, Analysis Group Inc, Los Angeles, California, United States
- Lewing, Benjamin, Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, Maryland, United States
- Norouzi, Sayna, Loma Linda University, Loma Linda, California, United States
- Chao, Ariel, Analysis Group Inc, Los Angeles, California, United States
- Rui, Shumin, Analysis Group Inc, Los Angeles, California, United States
- Betts, Keith A., Analysis Group Inc, Los Angeles, California, United States
- Lerma, Edgar V., Associates In Nephrology SC, Chicago, Illinois, United States
Background
In IgAN, systemic corticosteroids may slow disease progression but are associated with safety concerns. Real-world evidence on the clinical burden of corticosteroid-related adverse events is well established; however, evidence on their associated economic burden remains limited.
Methods
Adult patients with IgAN were identified from the Merative MarketScan databases. Eligible patients had ≥1 IgAN-specific diagnosis claim (ICD-10-CM N02.B). Corticosteroid users had ≥1 corticosteroid claim after IgAN diagnosis, with the first claim as index. Non-corticosteroid users had no corticosteroid claims and were assigned a randomly selected claim date as index. Patients were required to have an index date on or after January 1, 2019, and 12-month continuous enrollment pre- and post-index. Non-users were standardized mortality ratio-weighted to match corticosteroid users on clinical and demographic characteristics. Adverse clinical outcomes, healthcare resource utilization (HCRU), and costs were assessed over 12 months. Risk differences (RDs) were estimated using weighted linear probability models with robust standard errors. Mean differences in HCRU and costs were estimated with 95% confidence intervals (CIs) derived via bootstrap.
Results
A total of 171 corticosteroid users and 120 non-users were included. After weighting, mean age was 45 years, 44% were female, and the mean Charlson Comorbidity Index was 0.8. Corticosteroid users had significantly higher risk of overall adverse outcomes (57.3% vs. 42.8%; RD: 14.5% [95% CI: 0.8%, 28.3%]; p=0.04), incident or worsening hypertension (17.5% vs. 7.7%; RD: 9.8% [2.2%, 17.5%]; p=0.01) and serious infections (9.4% vs. 3.2%; RD: 6.4% [0.9%, 12.0%]; p=0.02). They also had more all-cause hospitalizations (0.14 vs 0.01; Δ=0.13 [0.05, 0.23]; p<0.01) and emergency visits (0.61 vs 0.17; Δ=0.45 [0.23, 0.66]; p<0.01). Mean annual all-cause healthcare costs were higher among corticosteroid users ($28,284 vs $3,764; Δ=$24,520 [14,249, 38,534]; p<0.01), driven by hospitalization, outpatient, and pharmacy costs. Adverse outcome–related HCRU and costs were similarly higher (total medical costs: $10,948 vs $755; Δ=$10,193 [2,908, 21,490]; p<0.01).
Conclusion
Corticosteroid use was associated with higher risk of adverse clinical outcomes and greater HCRU and costs in IgAN, underscoring substantial clinical and economic burden.
Funding
- Commercial Support – Otsuka Pharmaceutical Development & Commercialization, Inc.